Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update
Arcus Biosciences reported Q3 2026 revenue of $9 million (down from $26 million a year ago as Gilead collaboration revenues wind down) and a net loss of $128 million, with cash and marketable securities of $694 million plus $288 million in October equity proceeds funding operations into 2029. The pipeline story centers on casdatifan: ARC-20 data showed median PFS of 14.5 months in second-line ccRCC with cabozantinib, and unprecedented median OS of 35 months in late-line patients, exceeding third-party benchmarks.
Key figures
- Eps
- -1
- Revenue
- $9 million
- Guidance
- Full-year 2026 GAAP revenue of $70-$75 million
- Revenue Yoy
- -65%
- Cash runway
- into 2029
- Late line cor
- 36%
- First line cor
- 50%
- Net loss q3 2026
- $128 million
- Ga expense q3 2026
- $23 million
- Late line median os
- 35 months
- Late line median pfs
- 13 months
- Second line median pfs
- 14.5 months
- R and d expense q3 2026
- $117 million
- First line 12mo landmark pfs
- 69%
- October equity gross proceeds
- $288 million
- Cash and marketable securities
- $694 million
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.